Hologic Inc. (NSDQ:HOLX) is getting a late boost, with shares now up nearly 3.5 percent after the women’s health firm said a federal appeals court reversed an earlier decision siding with SenoRx Inc., now part of C.R. Bard (NYSE:BCR), in a patent infringement dispute.
C.R. Bard Inc. (NYSE:BCR) was just a cent shy of analysts’ expectations for its fourth quarter earnings, although the company fell far short of expected profits for the year.
The Murray Hill, N.J.-based company posted net earnings of $136.2 million, or $1.47 per diluted share, on sales of $717.1 million during the three months ended Dec. 31. That compares with net earnings of $105.9 million, or $1.08 per diluted share, on sales of $676.9 million during the same period last year.
Spire Corp.’s (NSDQ:SPIR) medical device unit sued Creganna-Tactx Medical subsidiary Catheter and Disposable Technology Inc. over an alleged breach of contract related to the manufacture of hemodialysis catheters.
The unit, Spire Biomedical Inc., yesterday filed a suit in U.S. District Court in Massachusetts alleging that CDT failed to assemble the catheters in accordance with its designs.
Hollister Inc. filed a pair of lawsuits against C.R. Bard Inc. (NYSE:BCR) and ConvaTec Inc., accusing the duo of infringing a patent covering its bowel waste management system.
The Libertyville, Ill.-based firm’s suits accuse Bard and ConvaTec of violating its patent for a “Bowel Management System And Waste Collection Bag Therefor.” Bard’s allegedly infringing device is its DigniCare stool management system; ConvaTec is alleged to infringe the patent with its Flexi-Seal and Flexi-Seal Signal fecal management systems.
Guide Flow LLC filed a lawsuit against six other firms, accusing them of infringing its patent for a "Catheter Guidewire and Flushing Apparatus and Method of Insertion."
The Newport Beach, Calif.-based firm accused C.R. Bard Inc. (NYSE:BCR), AngioDynamics Inc. (NSDQ:ANGO), Becton, Dickinson & Co. (NYSE:BDX), Medical Components Inc., Navilyst Medical Inc. and Smiths Medical ASD Inc. of violating the patent in a suit filed in the U.S. District Court for Utah.
A North Carolina couple will collect $1.5 million from C.R. Bard Inc. (NYSE:BCR) after a jury ruled in their favor in a product liability lawsuit over one of Bard’s line of hernia-repair products.
C.R. Bard Inc.’s (NYSE:BCR) peripheral vascular unit sued a pair of competitors over a patent covering its prosthetic vascular grafts made from expanded polytetrafluoroethylene.
The lawsuit, filed in the U.S. District Court for Arizona, accuses Endologix Inc. (NSDQ:ELGX) and Atrium Medical Corp. of infringing Bard’s patent for "Prosthetic Vascular Graft." Bard alleges that Atrium’s Advanta line of grafts and stents, its iVena vascular patch and Flixene graft violate the patent and that Endologix runs afoul with its Powerlink stent grafts.
The Food & Drug Administration is recommending that physicians consider removing retrievable inferior vena cava filters after logging 921 reports of "adverse events" related to the devices.
The federal watchdog agency warned that certain IVC filters could fracture, causing pieces of the device to travel through the bloodstream to other parts of the body.
A strong dollar was just enough to bulk up second-quarter results at C.R. Bard Inc. (NYSE:BCR) as the surgical, vascular and oncology technology company out-muscled Wall Street expectations.
The Murray Hill, N.J.-based medical device company reported $124.6 million in second-quarter profits on $673.9 million in net sales. Earnings rose 11 percent over year-ago levels, reaching $1.29 a share, although after acquisition-related expenses and certain write-downs adjusted earnings grew to $1.39 a share, beating the consensus analyst forecast by 3 cents.